Drug Database
US

ustekinumab (Qoyvolma)

✓ Approved

Celltrion, Inc. · IL12B · Monoclonal Antibodies

What is ustekinumab?

ustekinumab is a monoclonal antibodies developed by Celltrion, Inc.. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesQoyvolma
CompanyCelltrion, Inc.
Drug ClassMonoclonal Antibodies, Antibody
Molecular TargetIL12B, IL23A
RouteInjectable (Others), Intravenous (IV)
StatusApproved

Mechanism of Action

Molecular Targets

ustekinumab acts on 2 molecular targets:

IL12Binterleukin 12B (CLMF2, CLMF)
IL23Ainterleukin 23 subunit alpha (P19, SGRF)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

ustekinumab is developed for 4 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Gastrointestinal disordersColitis ulcerative✓ Approved
Gastrointestinal disordersCrohn's disease✓ Approved
Skin and subcutaneous tissue disordersPsoriasis✓ Approved
Musculoskeletal and connective tissue disordersPsoriatic arthropathy✓ Approved

Related Research Articles

PubMedChemPlusChem2026-08-31

Synergistic Role of Co0 and Lewis Basic Sites for Transfer Hydrogenation of Substituted Nitroarenes by In Situ Hydrogen Generation.

Sharma Anitya A, Ramchiary Dhanmani D, Sharma Devendra D, Kumar Sahil S et al.

Designing green and efficient methods for synthesizing anilines remains a key challenge in synthetic organic chemistry. Hydrogenation of nitro compounds is one of the most significant and widely employed method for producing functionalized anilines. Consequently, designing catalytic systems capable of hydrogenating nitroarenes under environmentally benign and mild reaction conditions remains a challenge. In this regard, a highly efficient CoAl catalyst has been designed for the hydrogenation of nitroarenes to corresponding amines. Various structural, compositional, and morphological characterizations were done to understand the catalyst's structural and surface properties. The as-synthesized catalyst exhibits excellent activity for the transfer hydrogenation of 1-chloro-4-nitrobenzene to 4-chloroaniline, achieving 98% yield at 60 °C within 1.5 h in ethanol. The developed protocol demonstrated excellent activity for wide range of substituted nitroarenes. Structure-activity relationships of CoAl show that basic sites play a crucial role in the transfer hydrogenation. Furthermore, mechanistic investigations reveal that transfer hydrogenation occurs predominantly via a hydroxylamine-mediated pathway. Moreover, the catalyst maintains good catalytic activity up to four consecutive cycles. This method eliminates the need for high-pressure H2, offering a safe strategy for aromatic amine synthesis. The work demonstrates the potential of earth-abundant, non-noble-metal-based heterogeneous catalysts for hydrogenation reactions under environmentally benign conditions.

PubMedCureus2026-08-30

Multisystem Benefits of GLP-1 Microdosing: A Narrative Review.

Panlilio Mia A MA, Piserchio Natalie N, Hennessey Mercedes M, Torres Kayla K et al.

Glucagon-like peptide-1 (GLP-1) is an endocrine hormone that plays a role in lowering blood glucose levels and promoting weight loss. GLP-1 receptor agonists (GLP-1 RAs) are synthetic peptides that mimic the activity of GLP-1, and the recent development of GLP-1 RA medications has been a major historical advancement in the treatment of diabetes and obesity. Despite the rapid development of GLP-1 RA medications, there is a very high demand for the limited supply of these drugs, resulting in high medication costs and significant care gaps among prescribed patients. This shortage has forced providers to be more strategic and creative with their treatments in order to support therapeutic continuity, which has led to an increased utilization of medication microdosing. This article aims to summarize available evidence on the effects of GLP-1 RAs and the possible benefits of long-term microdosing GLP-1 RA medications.

PubMediScience2026-08-30

DVE-1 is a telomere-binding protein and links the NuRD complex to telomere regulation in C. elegans.

Sluka Jan J, Blake Alexandra A, Podvalnaya Nadezda N, Fradera-Sola Albert A et al.

Telomeres are repetitive DNA sequences at the ends of linear chromosomes bound by specialized proteins. In our previous quantitative proteomics screen for telomere-binding proteins of Caenorhabditis elegans, we identified DVE-1, a homolog of mammalian SATB proteins and a transcription factor, as a telomere repeat-binding protein. Here, we validate DVE-1 as a telomere-binding protein in C. elegans, demonstrating in vitro binding of DVE-1 to the single-stranded C-rich telomeric sequence and in vivo co-localization with the telomere-binding protein POT-1. RNA interference-mediated knockdown of dve-1 resulted in reduced TERRA expression and enhanced compaction of telomeric chromatin. Subsequent transcriptomic and proteomic analyses suggest a role for DVE-1 in the regulation of telomeric chromatin organization. Finally, DVE-1 immunoprecipitation followed by mass spectrometry revealed all the core components of the nucleosome remodeling and deacetylase (NuRD) complex as interaction partners, implicating DVE-1 in the coordination of NuRD complex activity in the context of telomere organization.

PubMedEMBO reports2026-08-30

An evolutionarily conserved N-terminal domain of RRF-3 governs GTSF-1 binding in nematodes.

Govind Shamitha S, Ruppert Sebastian S, Kirangwa Joseph J, Busetto Virginia V et al.

GTSF1 is an essential activating cofactor for PIWI proteins in many metazoans. In the nematode Caenorhabditis elegans, however, GTSF-1 does not bind PIWI, but is associated with the RNA-dependent RNA polymerase RRF-3, supporting endo-siRNA (26G-RNA) biogenesis. Here, we demonstrate that this rewiring is deeply conserved across nematodes. For C. briggsae and Pristionchus pacificus, we show that GTSF-1 interacts with RRF-3 and is essential for 26G-RNA production and fertility. We map this interaction to an N-terminal domain of RRF-3, termed the GTSF-1 interacting domain (GID), and show that the GTSF-1 zinc finger region alone is sufficient for binding. Mutagenesis identifies critical residues mediating this interaction and reveals that GTSF-1 stability depends on RRF-3. Other RdRPs possess GID-like domains, which we propose to bind GTSF-1-related proteins. Phylogenomic and structural analyses support GTSF-1-RRF-3 interactions across all major nematode lineages and map the shift in GTSF-1 activity to the last common nematode ancestor. We propose that binding of GTSF-1 induces conformational changes in RRF-3 that facilitate RdRP complex assembly and activate its function, paralleling its role as a PIWI activator.

PubMediScience2026-08-30

Atractylenolide I stabilizes HMOX1 to induce ferroptosis and enhance lenvatinib efficacy in hepatocellular carcinoma.

Miao Yangyang Y, Jin Shengjie S, Peng Rui R, Tu Daoyuan D et al.

Lenvatinib resistance limits the therapeutic efficacy of hepatocellular carcinoma (HCC), highlighting the need for effective strategies to enhance treatment response. Atractylenolide I (AT-1), a bioactive compound derived from Atractylodes macrocephala, exhibits antitumor activity, yet its mechanism in HCC remains unclear. Here, we demonstrate that AT-1 suppresses HCC growth by inducing ferroptosis and enhances Lenvatinib efficacy. AT-1 increases intracellular Fe2+ accumulation, lipid peroxidation, and reactive oxygen species, consistent with ferroptotic cell death. Mechanistically, AT-1 directly binds to heme oxygenase-1 (HMOX1) and stabilizes its protein expression by inhibiting ubiquitination at lysine residues K177 and K179, thereby preventing proteasomal degradation. Genetic or pharmacological inhibition of HMOX1 abrogates AT-1-induced ferroptosis and antitumor effects in vitro and in vivo. Notably, AT-1 synergistically enhances Lenvatinib-mediated tumor suppression in HCC models. These findings identify HMOX1 stabilization as a core ferroptosis-regulating mechanism and support AT-1 as a promising adjuvant strategy for HCC therapy.

PubMedJournal of invertebrate pathology2026-08-30

Bombyx mori lipase-1 reduces viral replication and proliferation by inhibiting the expression of the DNA-binding protein (dbp) gene.

Chen Haiyu H, Ding Xiangrui X, Wang Jinyang J, Zhao Qiaoling Q et al.

Bombyx mori lipase-1 (Bmlipase-1) has strong anti-BmNPV activity, but the mechanism by which Bmlipase-1 resists BmNPV invasion has not been elucidated so far. In this paper, based on the construction of recombinant viruses overexpressing Bmlipase-1, we analyzed the effects of the recombinant viruses on the genes related to recombinant virus replication as well as viral replication and proliferation after the recombinant viruses infected BmN cells. In the presence of the virus, Bmlipase-1 localizes to the cell nucleus. Quantitative polymerase chain reaction (qPCR), northern blotting and western blot analyses showed that Bmlipase-1 inhibited the expression of BmNPV DNA-binding protein (dbp) as well as the replication and proliferation of the recombinant virus. DBP is a key factor for normal viral DNA replication and for the stabilization of nascent viral DNA. A biotin-labeled probe was synthesized around the c-Myb transcription factor binding site in the upstream promoter region of dbp and analyzed by EMSA with prokaryotically expressed and purified Bmlipase-1. It was found that Bmlipase-1 could bind to CACTTCAATT in the dbp promoter region, while the activity of the dbp promoter lacking CACTTCAATT was significantly reduced. In conclusion, Bmlipase-1 can bind to the CACTTCAATT motif on the dbp promoter in vitro, and this motif contributes positively to the activity of the dbp promoter. Overexpression of Bmlipase-1 significantly downregulates dbp expression and inhibits viral replication. Based on these findings, we propose the following hypothesis: Bmlipase-1 may inhibit viral replication by binding to the CACTTCAATT motif and interfering with the transcriptional regulation of dbp. However, this regulatory model requires further validation in the context of viral infection. This paper provides a new theoretical basis for the prevention and control of lepidopteran insect viruses, and also opens up a new way to study the antiviral mechanism of the silkworm, Bombyx mori.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about ustekinumab